Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program
PRINCETON, N.J. & MENLO PARK, Calif.–(BUSINESS WIRE)–#immunotherapy–Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization…